Phaseline

Companies › CytoDyn

CytoDyn: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Neurology, Infectious disease, Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
leronlimab
C-C chemokine receptor type 5 antagonist
CCR5Phase 2Metastatic Colorectal Cancer (mCRC); HIV - Human Immunodeficiency Virus; Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07903441leronlimabPhase 2HIV - Human Immunodeficiency VirusInfectious diseaseJul 2027
NCT07553338leronlimabPhase 2Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseNeurologyNov 2027
NCT06699836leronlimabPhase 2Metastatic Colorectal Cancer (mCRC)OncologyJan 2028

From the company's SEC filings

Cash of $16m on 2026-08-31; operating cash outflow about $31m a year; runway about 6 months at that burn, to Mar 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CCR5 (1)

Companies with the same targets

–

Companies built like this

Acumen Pharmaceuticals Y-mAbs Therapeutics Agenus CatalYm Alethia Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.